The Gene Business: Who Should Control Biotechnology?
Description:
The Gene Business, the first detailed, analytic study of the corporate agenda for biotechnology, takes a close look at the for-profit use of genetic engineering and molecular biology. Alarmed by the possible long-term effects of corporate-controlled university research, which places decision-making power in the hands of expedient and sometimes short-sighted board members, Yoxen provides a readable account of how genetic engineering evolved from a pure science into a profitable business. With the intent of sparking public interest in biotechnology, he examines the structure and function of today's multinational gene business, the effects it has had to date, and its scientific, economic, social and political implications.
The Gene Business includes a short history of molecular biology and a basic, non-technical explanation of genetic engineering to provide readers with the background necessary to understand the biotechnological revolution. The first such book aimed at the general reader, it is sure to stir controversy and to raise questions about the direction in which biotechnology is leading us.
Best prices to buy, sell, or rent ISBN 9780195040425
Frequently Asked Questions about The Gene Business: Who Should Control Biotechnology?
The price for the book starts from $5.28 on Amazon and is available from 3 sellers at the moment.
If you’re interested in selling back the The Gene Business: Who Should Control Biotechnology? book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the The Gene Business: Who Should Control Biotechnology? book, the best buyback offer comes from and is $ for the book in good condition.
The The Gene Business: Who Should Control Biotechnology? book is in very low demand now as the rank for the book is 11,396,375 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.
Not enough insights yet.